Patent · US Active

Copy number aberration driven endocrine response gene signature

US9890430B2 · kind B2 · utility

0Cited by
2References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 12, 2013
Grant dateFeb 13, 2018
Priority date—
Expiry dateApr 30, 2034

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/60
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Disclosed are methods of predicting the likelihood of long-term survival without recurrence of breast cancer for a subject having estrogen receptor-positive (ER+) breast cancer treated with adjuvant endocrine monotherapy. In various embodiments, these methods comprise performing a gene expression profile of a breast tissue sample of substantially all of the genes of the “CADER set” described herein; calculating a risk score using a regression model; and applying a double median cutoff classification to assign the subject to a sensitive, indeterminate or resistant group, wherein assignment to a sensitive group predicts longer relapse-free survival compared to the median relapse-free survival of ER+ breast cancer patients treated with adjuvant endocrine monotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.